146 related articles for article (PubMed ID: 9142156)
1. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection.
Schnitzler MA; Woodward RS; Brennan DC; Spitznagel EL; Dunagan WC; Bailey TC
Surgery; 1997 May; 121(5):563-8. PubMed ID: 9142156
[TBL] [Abstract][Full Text] [Related]
2. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation.
Schnitzler MA; Woodward RS; Brennan DC; Spitznagel EL; Dunagan WC; Bailey TC
Am J Kidney Dis; 1997 Mar; 29(3):428-34. PubMed ID: 9041220
[TBL] [Abstract][Full Text] [Related]
3. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
4. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation.
Smiley ML; Wlodaver CG; Grossman RA; Barker CF; Perloff LJ; Tustin NB; Starr SE; Plotkin SA; Friedman HM
Transplantation; 1985 Aug; 40(2):157-61. PubMed ID: 2992130
[TBL] [Abstract][Full Text] [Related]
5. Prevention of CMV infection by screening for CMV antibodies in renal allograft recipients and their blood and kidney donors.
Metselaar HJ; Ploeg RJ; Van Loon AM; Weiland HT; Rothbarth PH; Paul LC; Brand A; Schaafsma R; Hendriks GF; Jeekel J
Scand J Infect Dis; 1988; 20(2):135-9. PubMed ID: 2840730
[TBL] [Abstract][Full Text] [Related]
6. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis.
Ljungman P; Brand R; Einsele H; Frassoni F; Niederwieser D; Cordonnier C
Blood; 2003 Dec; 102(13):4255-60. PubMed ID: 12933590
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study.
Pollak R; Barber PL; Prusak BF; Mozes MF
Ann Surg; 1987 Mar; 205(3):302-4. PubMed ID: 3030201
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting graft and patient survival after live donor kidney transplantation in the UK.
Fuggle SV; Allen JE; Johnson RJ; Collett D; Mason PD; Dudley C; Rudge CJ; Bradley JA; Watson CJ;
Transplantation; 2010 Mar; 89(6):694-701. PubMed ID: 20308863
[TBL] [Abstract][Full Text] [Related]
10. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
[TBL] [Abstract][Full Text] [Related]
13. Living donor risk model for predicting kidney allograft and patient survival in an emerging economy.
Zafar MN; Wong G; Aziz T; Abbas K; Adibul Hasan Rizvi S
Nephrology (Carlton); 2018 Mar; 23(3):279-286. PubMed ID: 27943514
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.
Schmidt-Hieber M; Tridello G; Ljungman P; Mikulska M; Knelange N; Blaise D; Socié G; Volin L; Blijlevens N; Fegueux N; Yakoub-Agha I; Forcade E; Maertens J; Chevallier P; Passweg J; Cornelissen J; Russell N; Craddock C; Bourhis JH; Marchand T; Reményi P; Cahn JY; Michallet M; Montoto S; Kröger N; Glaß B; Styczynski J
Ann Hematol; 2019 Jul; 98(7):1755-1763. PubMed ID: 30993417
[TBL] [Abstract][Full Text] [Related]
15. Transplantation results of completely HLA-mismatched living and completely HLA-matched deceased-donor kidneys are comparable.
Laging M; Kal-van Gestel JA; Haasnoot GW; Claas FH; van de Wetering J; Ijzermans JN; Weimar W; Roodnat JI
Transplantation; 2014 Feb; 97(3):330-6. PubMed ID: 24202143
[TBL] [Abstract][Full Text] [Related]
16. HLA Matching in Pediatric Kidney Transplantation: HLA Poorly Matched Living Donor Transplants Versus HLA Well-Matched Deceased Donor Transplants.
Opelz G; Döhler B; Middleton D; Süsal C;
Transplantation; 2017 Nov; 101(11):2789-2792. PubMed ID: 28471872
[TBL] [Abstract][Full Text] [Related]
17. Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival.
Fitzgerald JT; Gallay B; Taranto SE; McVicar JP; Troppmann C; Chen X; McIntosh MJ; Perez RV
Transplantation; 2004 May; 77(9):1405-11. PubMed ID: 15167599
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
19. The impact of cytomegalovirus infection on seronegative recipients of seropositive donor kidneys versus seropositive recipients treated with cyclosporine-prednisone immunosuppression.
Johnson PC; Lewis RM; Golden DL; Oefinger PE; Van Buren CT; Kerman RH; Kahan BD
Transplantation; 1988 Jan; 45(1):116-21. PubMed ID: 2827353
[TBL] [Abstract][Full Text] [Related]
20. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
